Navigation Links
Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma
Date:6/1/2008

Updated Clinical Phase 2 data presented at American Society of Clinical

Oncology Annual Meeting

PRINCETON, N.J., June 1 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced updated long-term follow-up and overall survival (OS) results from a Phase 2 clinical study (MDX010-08) of 3 mg/kg of ipilimumab in combination with dacarbazine (DTIC) where 11.4%, or 4 of 35 patients, were still alive at or greater than 4 years of follow-up. This included 1 patient that experienced a complete response (4.7 years), 1 patient that experienced a partial response (4.2 years), 1 patient with stable disease (4.6 years) and 1 patient with RECIST defined progressive disease (4.4 years). The median OS for patients treated with ipilimumab in combination with DTIC was 15 months in this study. These results compare favorably with data in medical literature, in which median OS ranges from 6 to 9 months for patients with treated or previously untreated advanced melanoma treated with standard chemotherapy. These findings were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO), being held in Chicago, IL May 30-June 3, 2008. (Abstract # 9022)

"The long-term survival data suggests that ipilimumab in combination with DTIC may have long-lasting effects," said Geoffrey M. Nichol, MBChB, Senior Vice President of Product Development at Medarex. "With a median survival of approximately 15 months in the patients treated with 3 mg/kg of ipilimumab in combination with DTIC in this Phase 2 study, we look forward with interest to the outcome of the ongoing Phase 3 study being performed by our collaborator Bristol-Myers Squibb Company, comparing 10 mg/kg of ipilimumab in combination with DTIC versus DTIC alone in previously-untreated patients with advanced melanoma."

In the Phase 2 trial (MDX010-08), 72 chemotherapy-naive patients with advanced melanoma were treated with 3 mg/kg of ipilimumab monthly for four months and were randomized to receive either ipilimumab in combination with DTIC (n=35) or ipilimumab alone (n=37). Patients originally treated in the MDX010-08 study were subsequently enrolled into study MDX010-028 to determine long-term follow-up data and OS. The disease control rate (proportion of patients with complete responses, partial responses or stable disease) for patients treated with ipilimumab in combination with DTIC was 37.1%, or 13 of 35 patients, with 2 complete responses, 3 partial responses and 8 patients with stable disease. Two of 37 patients, or 5.4%, treated with 3 mg/kg of ipilimumab alone experienced partial responses, which were ongoing more than 4 years and 4.2 years in duration, respectively. The disease control rate in the ipilimumab alone treatment arm was 21.6%, or 8 of the 37 patients, with median OS of 12 months.

Ipilimumab is being developed through a joint partnership between Bristol-Myers Squibb and Medarex. Based on preclinical and clinical studies showing that antibody blockade of CTLA-4 plays an important role in sustaining an active immune response to fight cancer, the companies are pursuing a broad clinical development program with ipilimumab. More than 2,000 patients have been treated in clinical trials with ipilimumab as a monotherapy or in combination with other agents. Patients in the ongoing Phase 3 study (BMS study CA184-024) are randomized to receive induction therapy with 10 mg/kg of ipilimumab in combination with DTIC or placebo. Eligible patients are permitted maintenance dosing with ipilimumab or placebo after the induction phase has been completed.

For further information about ipilimumab clinical trials, please visit http://www.clinicaltrials.gov.

About Ipilimumab

Ipilimumab is a fully human antibody that binds to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), a molecule on T-cells that plays a critical role in regulating natural immune responses. The absence or presence of CTLA-4 can augment or suppress the immune system's T-cell response in fighting disease. Ipilimumab is designed to block the activity of CTLA-4, thereby sustaining an active immune response in its attack on cancer cells.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its Web site at http://www.medarex.com.

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "suggests"; "potential"; or "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. These risks and uncertainties include whether the actual results in the clinical studies described above will differ materially from results in future use of ipilimumab, whether development of ipilimumab will be successful, whether the clinical studies described in this release will support the filing of a BLA with the FDA, or whether, if a BLA is filed with the FDA, it will be filed in the timeframe developed by the parties or will receive regulatory approval, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its quarterly reports on Form 10-Q. There can be no assurance that such development efforts will succeed or that other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
2. Medarex Announces Ipilimumab Program Continues to Move Forward
3. New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
4. Genasense(R) Chemotherapy Program Yields High Response Rate in Patients with Stage 4 Melanoma
5. Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy
6. Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
7. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
8. Studies Point to Benefits of Personalized Chemotherapy Dose Management in Colorectal Cancer
9. Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells
10. Totality of Available Data Reaffirms PROCRIT(R) (Epoetin alfa) Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy-Induced Anemia
11. Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... MENLO PARK, Calif. , Oct. 11, 2017 /PRNewswire/ ... a national scientific team that developed an innovative way ... and quantity of the delivery of new drugs. ... the 2017 Fall Clinical Dermatology Conference will show how ... Massachusetts General Hospital, Harvard Medical School used a suite ...
(Date:10/10/2017)...  NDS received FDA 510(k) clearance in May 2017 for its ... specifically designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... to support the improvement of patient outcomes, procedural efficiency, and the ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
Breaking Medicine News(10 mins):